Assembly Biosciences Inc. (ASMB) stock soar during pre-market. Here’s to know why?

Assembly Biosciences Inc. (NASDAQ: (ASMB) stock declined by 1.70% at last close whereas the ASMB stock price gained by 3.81% in the pre-market trading session. Assembly Bio is a clinical-stage biotechnology firm dedicated to developing finite and curative hepatitis B virus (HBV) medicines for the world’s 270 million individuals living with the illness.

ASMB stock’ Financial Highlights

For the third quarter of 2021, Assembly Biosciences released financial outcomes and recent highlights.

• For the third quarter of 2021, cash, cash equivalents, and marketable securities were $190.1 million, compared to $199.1 million in the second quarter of 2021.
• Revenue from joint research was $6.3 million in the third quarter of 2021, relative to $34.6 million for the same time in 2020.
• For the third quarter of 2021, research and development expenses were $18.5 million, relative to $26.9 million for the same time in 2020.
• For the third quarter of 2021, general and administrative expenses were $6.7 million, relative to $11.7 million for the same time in 2020.
• The net loss attributable to common stockholders was $18.8 million, or $0.41 per basic and diluted share for the third quarter of 2021 while it was $3.3 million, or $0.09 per basic and diluted share, for the same period in 2020.

John McHutchison, AO, MD, CEO and president of Assembly Bio, commented,

They’re pleased to progress ABI-4334, their newest core inhibitor, and they’re working hard to get this candidate into clinical trials as soon as feasible next year. In the meantime, they’ve increased the number of triple combination regimens they’re testing to treat HBV. It also includes vebicorvir (VBR), their main experimental core inhibitor candidate, as a core therapy, as well as standard-of-care nucleos(t)ide reverse transcriptase inhibitor (Nrtl) therapy and a complementary mechanism. Interferon (peg-IFN) and Arbutus’ RNAi therapy candidate are currently in Phase 2 studies, and now the company is excited to start the third Phase 2 all-oral triple combination cohort with Antios ASPIN, ATI-2173. The first results from all three studies are expected in 2022.